These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9082095)

  • 1. [Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
    Leal M; Caruz A; Rey C; Lissen E
    Med Clin (Barc); 1996 Nov; 107(19):755. PubMed ID: 9082095
    [No Abstract]   [Full Text] [Related]  

  • 2. Relevance of AIDS treatment with two nucleoside analogues alone.
    Weidle PJ; Mbidde E; Djomand G; Lackritz EM
    Lancet; 1999 Jun; 353(9169):1989-90. PubMed ID: 10376610
    [No Abstract]   [Full Text] [Related]  

  • 3. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
    Rubio A; Gómez-Cano M; Puig T; Leal M; Pérez-Olmeda M; Ruiz L; Clotet B; Rey C; Zamora L; Xaus N; Soriano V
    Antivir Ther; 1999; 4(1):45-9. PubMed ID: 10682128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-HIV therapy (1987-1994): from nothing to confusion].
    Lissen E
    Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
    [No Abstract]   [Full Text] [Related]  

  • 7. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
    Antivir Ther; 2002 Mar; 7(1):11-20. PubMed ID: 12008783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of didanosine in the management of HIV-1 infection.
    Gazzard BG; Moyle GJ
    Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
    Husson RN; Shirasaka T; Butler KM; Pizzo PA; Mitsuya H
    J Pediatr; 1993 Jul; 123(1):9-16. PubMed ID: 8391570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research study of combination AIDS therapies underway.
    AIDS Patient Care STDS; 1996 Apr; 10(2):132. PubMed ID: 11361697
    [No Abstract]   [Full Text] [Related]  

  • 11. Zidovudine plus didanosine in primary HIV-1 infection.
    Perrin L; Yerly S; Charvier A; Figueras G; Schockmel GA; Hirschel B
    Antivir Ther; 1997 Jan; 2(1):5-11. PubMed ID: 11322267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
    Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC
    J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making sense of 175 and Delta.
    Smart T
    GMHC Treat Issues; 1995 Oct; 9(10):4. PubMed ID: 11362916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Committee recommends clearance for HIVID combination therapy.
    AIDS Patient Care STDS; 1996 Jun; 10(3):186. PubMed ID: 11361630
    [No Abstract]   [Full Text] [Related]  

  • 16. Top AIDS researchers' strategy for antiretroviral treatment.
    AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crixivan reduces viral load.
    AIDS Patient Care STDS; 1996 Feb; 10(1):50. PubMed ID: 11361665
    [No Abstract]   [Full Text] [Related]  

  • 18. Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain.
    Briones C; Soriano V
    Antivir Ther; 1999; 4(2):125-7. PubMed ID: 10682159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study results at a glance.
    AIDS Alert; 1995 Nov; 10(11):134. PubMed ID: 11362922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on reverse transcriptase inhibitors in HIV disease.
    Carr A; Loewenthal M; Cooper DA
    Isr J Med Sci; 1993 Oct; 29(10 Suppl):26-30. PubMed ID: 7503966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.